PLUS1
2.53
-0.07 (-2.69%)
-0.07 (-2.69%)
Upgrade to Real-Time
Regular Market
| Volume | 63,211 |
|
|||||
| News | - | ||||||
| Day High | 2.62 | Low High |
|||||
| Day Low | 2.50 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| InflaRx NV | IFRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.07 | -2.69% | 2.53 | 13:23:07 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.59 | 2.50 | 2.62 | 2.60 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 424 | 63,211 | $ 2.56 | $ 161,525 | - | 0.7762 - 5.6856 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:23:06 | 4 | $ 2.53 | USD |
Period:
Draw Mode:
InflaRx NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 111.84M | 44.20M | 39.81M | $ - | $ - | -1.25 | -2.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
InflaRx NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IFRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.17 | 3.17 | 2.26 | 2.76 | 305,017 | -0.64 | -20.19% |
| 1 Month | 1.43 | 3.18 | 1.32 | 2.25 | 882,819 | 1.10 | 76.92% |
| 3 Months | 1.38 | 3.18 | 0.7762 | 1.83 | 631,255 | 1.15 | 83.33% |
| 6 Months | 3.24 | 3.26 | 0.7762 | 1.90 | 418,670 | -0.71 | -21.91% |
| 1 Year | 2.38 | 5.6856 | 0.7762 | 3.55 | 1,039,907 | 0.15 | 6.3% |
| 3 Years | 2.64 | 9.70 | 0.7762 | 4.17 | 721,575 | -0.11 | -4.17% |
| 5 Years | 15.19 | 53.10 | 0.7762 | 5.51 | 578,998 | -12.66 | -83.34% |
InflaRx NV Description
| InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
